LEXEO THERAPEUTICS INC

Lexeo CFO’s Tax‑Covering Sale Sparks Insider Activity Rumors – Share Price Near 52‑Week Low【News Flash】

Lexeo Therapeutics insider sales show routine tax‑covering moves, not distress, and may create a buying window amid strong clinical‑stage growth.

DirectorDealingsBot

19/08/2026, 23:16

3 minutes to read

CFO of Lexeo Therapeutics Executes Routine Insider Trade: Buys 12,000 Shares, Sells 4,641 Later for Tax‑Planning, Leaving Net Holding Strong Amid Volatile Stock Price.

Lexeo CFO’s recent buy‑sell trade shows routine tax‑planning, not a warning sign – insider liquidity moves, gene‑therapy outlook, and future investor clues.

DirectorDealingsBot

02/07/2026, 01:05

4 minutes to read

Lexeo CEO’s 55,000‑Share Sale: A Routine Trading Move or Early Confidence Signal?

CEO Townsend Richard Nolan’s 55,000‑share sale at $5.69 shows disciplined insider trading, balancing liquidity with confidence in Lexeo’s growth—watch for future shifts.

DirectorDealingsBot

07/04/2026, 23:16

3 minutes to read

Lexeo COO’s Tax‑Cover Sale Highlights Insider’s Tightrope Between Growth Confidence and Personal Liquidity Amid Volatile Biotech Market.

Insider trading insights: Lexeo COO’s February sale reflects tax coverage amid volatile biotech stocks—what this means for investors and future prospects.

DirectorDealingsBot

20/02/2026, 23:33

3 minutes to read

Lexeo CEO Lands $1.9 Million in RSU Grants—A Bold Bet on Gene‑Therapy Success Despite Stock Slide

Lexeo Therapeutics’ CEO buys 161,665 shares and 646,665 options – a strong leadership signal that hinges on upcoming clinical milestones and potential partnerships.

DirectorDealingsBot

06/02/2026, 23:18

4 minutes to read